Chapel Hill, NC, United States of America

Richard Jude Samulski

USPTO Granted Patents = 66 (Patent Applications = 24)

CIPO Patents = 5 (Patent Applications = 17)

EPO Patents = 14 (Patent Applications = 29)

Average Co-Inventor Count = 2.1

ph-index = 31

Forward Citations = 2,981(Granted Patents)

Forward Citations (Not Self Cited) = 2,803(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Princeton, NJ (US) (1992)
Chaphel Hill, NC (US) (1999)
Pittsburgh, PA (US) (1995 - 2005)
Chapel Hill, NC (US) (1998 - 2024)
Hillsborough, NC (US) (2020 - 2024)

Company Filing History:

45 out of 1,274

The University of North Carolina at Chapel Hill

patents

6 out of 1,866

University of Pittsburgh

Asklepios Biopharmaceutical, Inc.

patents

5. 3 out of 2,930

University of Florida Research Foundation Inc

patents

6. 3 out of 3

Bamboo Therapeutics, Inc.

patents

7. 1 out of 1

Asklepios Biopharmaceuticals, Inc.

patent

8. 4 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2025

Loading Chart...

Areas of Expertise:

Adeno-Associated Virus

Viral Vector Delivery

Gene Therapy

Modified Capsid Proteins

Blood-Brain Barrier

Chimeric Vectors

Parvovirus Vectors

Dual Glycan Binding

Optimized Mini-Dystrophin

Recombinant Virus Production

Factor VIII Genes

Heparin Binding Vectors

66 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12319715 - Modified capsid proteins for enhanced delivery of parvovirus vectors (2025-06-03),

2. 12281335 - Methods and compositions for delivery of viral vectors across the blood-brain barrier (2025-04-21),

3. 12257321 - Optimized mini-dystrophin genes and expression cassettes and their use (2025-03-25),

4. 12201697 - AAV-IDUA vector for treatment of MPS I-associated blindness (2025-01-21),

5. 12049478 - Methods and compositions for dual glycan binding AAV vectors (2024-07-30),

6. 11939597 - Restrictive inverted terminal repeats for viral vectors (2024-03-26),

7. 11905533 - Methods and compositions for delivery of viral vectors across the blood-brain barrier (2024-02-20),

8. 11702676 - Rational polyploid adeno-associated virus vectors for the treatment of disease (2023-07-18),

9. 11639509 - Methods and compositions for dual glycan binding AAV2.5 vector (2023-05-02),

10. 11547765 - Optimized mini-dystrophin genes and expression cassettes and their use (2023-01-10),

11. 11542478 - Restrictive inverted terminal repeats for viral vectors (2023-01-03),

12. 11414678 - Modified soluble VEGF receptor-1 genes and vectors for gene therapy (2022-08-16),

13. 11124546 - Modified capsid proteins for enhanced delivery of parvovirus vectors (2021-09-21),

14. 11116850 - AAV-IDUA vector for treatment of MPS I-associated blindness (2021-09-14),

15. 11059862 - Methods and compositions for dual glycan binding AAV vectors (2021-07-13),

Title: The Innovative Journey of Richard Jude Samulski

Introduction: Richard Jude Samulski, a pioneering inventor based in Chapel Hill, NC, has made significant contributions to the field of innovations and patents.

Latest Patents: Richard Jude Samulski holds several patents in various industries, showcasing his diverse range of expertise and creativity.

Career Highlights: With a career spanning several decades, Richard Jude Samulski has been at the forefront of groundbreaking inventions that have shaped industries and improved lives globally. His dedication to innovation is evident in the numerous patents he has successfully obtained.

Collaborations: Throughout his career, Richard Jude Samulski has collaborated with leading companies, research institutions, and universities to bring his inventions to life. His ability to work with diverse teams and experts has been instrumental in the success of his projects.

Conclusion: Richard Jude Samulski's passion for innovation, coupled with his relentless drive to push boundaries, has solidified his reputation as a visionary inventor. His contributions to the world of patents and inventions continue to inspire future generations of innovators.

This text is generated by artificial intelligence and may not be accurate.